Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data
Bio Expo
Champignondagen
  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press Releases

Intellia Therapeutics Secures FDA Clearance to Resume MAGNITUDE Phase 3 Trial in ATTR-CM

  • The Pharma Data
  • March 3, 2026

Intellia Therapeutics Reports FDA Clearance to Resume MAGNITUDE Phase 3 Study in ATTR-CM Following Removal of Clinical Hold Intellia Therapeutics has cleared a significant regulatory hurdle in its effort to…

Read MoreIntellia Therapeutics Secures FDA Clearance to Resume MAGNITUDE Phase 3 Trial in ATTR-CM
  • Regulatory

Royalty Pharma Names Kenneth Sun as SVP and Head of Asia to Strengthen Global Expansion Strategy

  • The Pharma Data
  • March 3, 2026

Royalty Pharma Names Kenneth Sun as Senior Vice President and Head of Asia, Strengthening Its Global Expansion Strategy and Regional Presence Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment…

Read MoreRoyalty Pharma Names Kenneth Sun as SVP and Head of Asia to Strengthen Global Expansion Strategy
  • News

Zoetis Expands Precision Animal Health Portfolio with Acquisition of Genomics Unit from Neogen

  • The Pharma Data
  • March 3, 2026

Zoetis moves to acquire the animal genomics unit of Neogen, strengthening its precision animal health capabilities.  Zoetis Inc. the world’s leading animal health company, today announced it has entered into…

Read MoreZoetis Expands Precision Animal Health Portfolio with Acquisition of Genomics Unit from Neogen
  • Research

Roche’s Fenebrutinib Confirms Potential as First BTK Inhibitor for MS in Third Positive Phase III Trial (FENhance 1)

  • The Pharma Data
  • March 3, 2026

Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III…

Read MoreRoche’s Fenebrutinib Confirms Potential as First BTK Inhibitor for MS in Third Positive Phase III Trial (FENhance 1)
  • Press Releases

AbbVie: SKYRIZI® Hits Positive Phase 3 Goals in Crohn’s

  • The Pharma Data
  • March 3, 2026

AbbVie Reports Positive Phase 3 Results for Subcutaneous SKYRIZI® in Crohn’s Disease AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating…

Read MoreAbbVie: SKYRIZI® Hits Positive Phase 3 Goals in Crohn’s
Wisdom
  • Research

Wisdom Bioscience Forms Scientific Advisory Board to Advance Oral Cancer Diagnostics

  • The Pharma Data
  • March 2, 2026

Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening Wisdom Bioscience, a biotechnology company revolutionizing oral cancer diagnostics, has announced the formation of its Scientific Advisory…

Read MoreWisdom Bioscience Forms Scientific Advisory Board to Advance Oral Cancer Diagnostics
FDA
  • Press Releases

FDA Accepts Takeda and Protagonist’s NDA for Rusfertide, a First-in-Class Treatment for Polycythemia Vera

  • The Pharma Data
  • March 2, 2026

Pivotal Study Shows Significant Improvements in Hematocrit Control and Patient Outcomes What does the future hold for patients with polycythemia vera (PV)? Takeda and Protagonist Therapeutics, Inc. have announced a…

Read MoreFDA Accepts Takeda and Protagonist’s NDA for Rusfertide, a First-in-Class Treatment for Polycythemia Vera
Genentech
  • Regulatory

Genentech’s Fenebrutinib Shows Significant Efficacy in Relapsing Multiple Sclerosis

  • The Pharma Data
  • March 2, 2026

Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission Why is the search for effective treatments for multiple sclerosis (MS) more urgent than…

Read MoreGenentech’s Fenebrutinib Shows Significant Efficacy in Relapsing Multiple Sclerosis
Novocure
  • News

Novocure to Showcase Tumor Treating Fields at Leerink Global Healthcare Conference

  • The Pharma Data
  • March 2, 2026

Novocure’s Leadership to Highlight Innovative Cancer Therapy at Prestigious Event Why should healthcare investors and oncology professionals be paying attention to Novocure’s upcoming participation in the Leerink Global Healthcare Conference?…

Read MoreNovocure to Showcase Tumor Treating Fields at Leerink Global Healthcare Conference
Cryo-Cell
  • BusinessPress Releases

Cryo-Cell International Reports Fiscal 2025 Results: Revenue Declines, Net Loss Recorded

  • The Pharma Data
  • March 2, 2026

Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc.…

Read MoreCryo-Cell International Reports Fiscal 2025 Results: Revenue Declines, Net Loss Recorded
Guardant Health
  • Press Releases

Guardant Health Grants Equity Awards to New Non-Executive Employees

  • The Pharma Data
  • March 2, 2026

Strategic Equity Incentives to Attract Talent and Drive Innovation Why is attracting and retaining top talent crucial for precision oncology companies? Guardant Health, a leading precision oncology company, is taking…

Read MoreGuardant Health Grants Equity Awards to New Non-Executive Employees
Prothena
  • Press Releases

Prothena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value

  • The Pharma Data
  • February 28, 2026

Prothena’s Strategic Move to Boost Shareholder Confidence and Financial Flexibility Why are biotechnology companies increasingly turning to share repurchase plans to optimize their financial strategies? Prothena Corporation plc, a late-stage…

Read MoreProthena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value
Next
Global Clinical
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Intellia Therapeutics Secures FDA Clearance to Resume MAGNITUDE Phase 3 Trial in ATTR-CM
  • Royalty Pharma Names Kenneth Sun as SVP and Head of Asia to Strengthen Global Expansion Strategy
  • Zoetis Expands Precision Animal Health Portfolio with Acquisition of Genomics Unit from Neogen
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.